Wegovy Coupons in 2026: Every Discount Option, Ranked by What You Actually Save

Key Takeaways

• The official Novo Nordisk Wegovy savings card lets commercially insured patients whose plan covers Wegovy pay as little as $25 per fill, with Novo covering up to $100 per month ($300 per 3-month fill); no $4,600 annual cap appears in the current terms.
• For patients without coverage, Novo's self-pay program (NovoCare Pharmacy, also honored at GoodRx-listed retail pharmacies) prices the pen at $199 a month for the first two fills (new patients, through December 31, 2026) then $349, Wegovy HD at $399, and the Wegovy pill at $149 to $299, per the April 2026 NovoCare Price Guide confirmed September 4, 2026.
• Medicare and Medicaid patients cannot use the savings card, but since July 1, 2026 eligible Medicare Part D patients pay $50 a month for any Wegovy pen or pill strength through the Medicare GLP-1 Bridge.
• GoodRx does not beat the manufacturer programs; as of September 2026 it simply surfaces Novo's own self-pay offer ($149 to $349) against an average retail price it lists as $1,643.
• Patient assistance through Novo Nordisk's PAP can provide free Wegovy to qualifying low-income patients with no insurance coverage.

The short answer

The main Wegovy coupon is the Novo Nordisk savings card, which lets commercially insured patients with coverage pay as little as $25 per fill (Novo pays up to $100 a month). Patients without coverage pay Novo's self-pay price: $199 a month for the first two pen fills then $349, or $149 to $299 for the Wegovy pill, as of September 4, 2026. Eligible Medicare patients pay $50 a month through the GLP-1 Bridge, and low-income uninsured patients may qualify for the Patient Assistance Program.

Table of contents

1. The 30-second answer
2. The Wegovy savings card: who qualifies and what it costs
3. WegovyDirect cash-pay program
4. Medicare and Medicaid: why the card doesn't apply
5. Patient Assistance Program for uninsured low-income patients
6. Why GoodRx and similar coupon sites don't help with Wegovy
7. The role of HSA and FSA dollars
8. What to do when no coupon brings the price into reach
9. Step-by-step: lowest possible Wegovy price for your situation
10. Every discount in one table
11. How long the coupon lasts
12. Medicare: $50 Bridge and the $2,100 cap
13. Stale and fake coupons
14. January 2027: the $675 list price
15. FAQ
16. Sources
17. Footer disclaimers

The Wegovy savings card: who qualifies and what it costs

The Novo Nordisk Wegovy savings card is the main "coupon" most patients are looking for. As of September 4, 2026, the terms published on novocare.com are:

• Eligibility: US residents with commercial (private/employer) insurance that covers Wegovy.
• Pay as little as $25 per 1-month fill if your commercial insurance covers Wegovy.
• No cash-floor tier: the current terms have no price for commercially insured patients whose plan does not cover Wegovy; those patients use the self-pay program instead.
• Maximum savings: $100 per 1-month prescription, $200 per 2-month, $300 per 3-month.
• Annual benefit cap: none is stated in the current terms; the per-fill cap does the limiting.
• Excluded: Medicare, Medicaid, Tricare, VA, and any other federal or state-funded coverage.

The card stacks with insurance. Insurance pays its contracted portion first, the card covers up to $100 of the remaining cost, and you pay the rest, with a floor of $25. If insurance denies coverage entirely, the card does not apply; compare Novo's self-pay price instead.

Activation takes a few minutes online at the Wegovy website. The card produces a BIN, PCN, and group number that the pharmacy enters at point of sale.

A common pitfall: the card doesn't help patients on Medicare even though some Medicare patients have supplemental commercial coverage. Once any portion of the prescription benefit is funded by Medicare, the card is excluded.

WegovyDirect cash-pay program

For patients without commercial insurance, or patients whose insurance refuses to cover Wegovy and who don't want to pay full retail, Novo Nordisk sells Wegovy at a self-pay price through NovoCare Pharmacy (the program some articles call WegovyDirect) and, since 2026, through retail pharmacies listed on GoodRx.

Per the April 2026 NovoCare Price Guide, confirmed on wegovy.com September 4, 2026:

Plan	What you get	Monthly cost
Wegovy pen, intro offer	0.25 mg and 0.5 mg, first two fills, new patients, through December 31, 2026	$199 per month
Wegovy pen, ongoing	Any dose 0.25 mg to 2.4 mg	$349 per month
Wegovy HD	7.2 mg pen	$399 per month
Wegovy pill	1.5 mg / 4 mg / 9 mg and 25 mg	$149 / $199 / $299 per month

Mechanics:

• Order through NovoCare Pharmacy, or fill at a participating retail pharmacy
• Telehealth consult (separate fee may apply if you don't have an existing prescription)
• Ships from a Novo Nordisk-affiliated pharmacy
• Monthly auto-refill subscription
• Cash payment, no insurance billing

The $349 ongoing pen price is about 74 percent below the $1,349.02 list price, and the $149 pill price is about 89 percent below it. The self-pay program's main competitor is compounded semaglutide through telehealth platforms, which had a September 2026 month-1 median of $197 in the FormBlends price index, is not FDA-approved and is not interchangeable with Wegovy.

For patients who want brand-name FDA-approved Wegovy and don't have insurance coverage, the Novo self-pay program is currently the lowest-cost legitimate option. The pen price is flat across doses after the intro offer; the pill is priced by strength.

Medicare and Medicaid: why the card doesn't apply

Federal anti-kickback rules prohibit drug manufacturers from offering copay coupons or savings cards to Medicare, Medicaid, Tricare, or VA patients. The reasoning: these patients' drugs are partly funded by federal dollars, and a manufacturer paying part of the patient's copay would be seen as steering the patient toward the manufacturer's drug at federal expense.

This means:

• A 67-year-old retiree on Medicare Part D cannot use the Wegovy savings card, period.
• A 45-year-old on Medicaid cannot use the card.
• A military family member with Tricare cannot use the card.

Medicare exception for cardiovascular Wegovy.

Wegovy received an FDA label expansion in March 2024 to reduce the risk of major adverse cardiovascular events in adults with overweight or obesity plus established cardiovascular disease. CMS issued guidance allowing Medicare Part D plans to cover Wegovy for this specific indication. Patients with documented CV disease (prior heart attack, stroke, or peripheral artery disease) plus BMI 27+ can request Wegovy coverage under their Part D plan.

Since July 1, 2026 there is a second, broader path: the Medicare GLP-1 Bridge, which covers all strengths of the Wegovy pen and pill for $50 a month through December 31, 2027 for beneficiaries who meet CMS criteria, with prior authorization. The cardiovascular path remains plan-specific; copays vary and the 2026 Part D out-of-pocket cap of $2,100 applies to it, while the Bridge's $50 sits outside that cap.

Medicaid coverage.

A handful of state Medicaid programs cover Wegovy for obesity. Most do not. Each state Medicaid sets its own preferred drug list. Coverage criteria when offered usually include BMI 30+ (or 27+ with comorbidity), documented prior weight-loss attempts, and provider certification.

If your state Medicaid does not cover Wegovy, the savings card cannot fill the gap because Medicaid is excluded.

Patient Assistance Program for uninsured low-income patients

The Novo Nordisk Patient Assistance Program (PAP) provides Novo medicines free to qualifying low-income patients; NovoCare's 2026 PAP page did not list Wegovy by name when we read it on September 4, 2026, so confirm it is on the current product list before applying. Eligibility criteria as of 2026:

• US resident or legal alien
• Total household income at or below 400% of the federal poverty level ($63,840 for one person, $132,000 for a family of four under the 2026 HHS guidelines)
• No prescription drug coverage, or coverage that doesn't include Wegovy and won't be made to cover it
• Not covered by Medicare, Medicaid, or other federal/state programs that would pay for the drug

Approval typically lasts 12 months and is renewable. Approved drug ships to the patient's provider's office. Ozempic has a tighter income limit (200 percent of the poverty level) than the other Novo products (400 percent), and Medicare beneficiaries with drug coverage are no longer eligible for Ozempic through the PAP.

For patients clearly meeting income criteria with no insurance and a documented obesity diagnosis (BMI 30+, or 27+ with comorbidity), the PAP is worth applying to. The application requires provider involvement and tax documentation of household income.

Why GoodRx and similar coupon sites don't help with Wegovy

GoodRx, SingleCare, Optum Perks, and similar pharmacy discount card services typically negotiate prices below cash retail by routing prescriptions through a PBM. They work well for generics and many older brand drugs, but they don't move the needle much for newer brand-only drugs like Wegovy.

Why:

• No generic exists. GLP-1s are still patent-protected. Discount card services rely heavily on generic substitution, which isn't an option here.
• Manufacturer rebate structure. Novo Nordisk's rebates flow to insurance plan PBMs, not to retail discount card programs. Retail discount card programs can't access those rebates.
• The manufacturer programs already discount. Novo's self-pay price of $149 to $349 is the floor, and GoodRx's Wegovy page now shows that same offer rather than a separate coupon.

If you check GoodRx for Wegovy in September 2026, you'll see "as low as $149" against an average retail price of $1,643; the $149 is Novo's pill offer, not a GoodRx discount. Novo's self-pay price is the bar to beat for cash-pay patients.

For a patient with no insurance, the order of preference is:

1. Apply for Novo Nordisk PAP if income qualifies (could be free)
2. Use Novo self-pay ($199 then $349 for the pen, $149 to $299 for the pill) if PAP isn't an option
3. Consider a state-licensed compounding pharmacy for compounded semaglutide (not FDA-approved, not interchangeable with Wegovy)
4. As a last resort, retail with a discount card

The role of HSA and FSA dollars

Wegovy is HSA- and FSA-eligible when prescribed for a qualifying medical condition. For commercial-insurance patients with high-deductible health plans, this matters more than it sounds.

How HSA helps:

• HSA contributions are pretax, federal-tax-free at withdrawal for qualified medical expenses, and (in most states) state-tax-free.
• A patient in a 24% federal bracket effectively gets a 24% discount on out-of-pocket Wegovy costs paid through HSA dollars.
• HSA contribution limits are set annually by the IRS; check the current-year limit before planning.

For a patient paying $200 a month out of pocket on Wegovy ($2,400 a year), running that through HSA is roughly equivalent to a $576 a year discount in a 24% bracket.

FSA works similarly with lower limits. Wegovy expenses must be incurred during the FSA plan year and submitted with proof of prescription.

What to do when no coupon brings the price into reach

If you've checked all of the above and Wegovy is still unaffordable, options narrow but don't disappear:

• Reapply for insurance coverage. Insurance denials are often overturnable. Document failed prior weight-loss attempts and BMI history.
• Check whether you qualify for the cardiovascular indication. If you have a history of MI, stroke, or peripheral artery disease plus BMI 27+, the Wegovy CV indication may open Medicare or insurance coverage.
• Consider compounded semaglutide. Available through state-licensed compounding pharmacies in response to an individual prescription. Compounded semaglutide is not FDA-approved, is not interchangeable with Wegovy, and pricing varies by provider. Quality varies between pharmacies; ask about USP 797 compliance and licensure status.
• Consider compounded tirzepatide. A different molecule with larger weight-loss results in trials. Same regulatory caveat.
• Wait for generic semaglutide. Patent expirations are still several years out for semaglutide in the US. This is not a near-term solution.

Most patients land on the savings card or WegovyDirect path. The PAP path applies to a narrower group.

Step-by-step: lowest possible Wegovy price for your situation

If you have commercial insurance:

1. Check whether your plan covers Wegovy. Call member services or check the plan formulary.
2. If covered, get the savings card and use it. Typical cost: $25 per fill if your copay is $125 or less; your copay minus $100 if it is higher.
3. If not covered, request a formulary exception or appeal. Provider's office handles this.
4. If the appeal fails, the card no longer has a cash-floor tier; move to Novo self-pay.
5. Compare with Novo self-pay ($349 for the pen after the intro, $149 to $299 for the pill) to see which is lower.

If you have Medicare Part D:

1. Check whether you qualify for the Medicare GLP-1 Bridge ($50 a month, July 1, 2026 to December 31, 2027; BMI of 35 or higher, or 30 or higher with heart failure, uncontrolled hypertension or chronic kidney disease stage 3a or above, or 27 or higher with pre-diabetes, prior heart attack, prior stroke or symptomatic peripheral artery disease), or for the cardiovascular indication.
2. If yes, request Wegovy coverage through your Part D plan with prior authorization documenting CV history.
3. If approved under the Bridge, you pay $50 a month outside the Part D deductible and cap; under the cardiovascular path, your plan's copay applies up to the 2026 cap of $2,100.
4. If not eligible, Wegovy is not covered. Look at Novo self-pay ($199 then $349 for the pen, $149 to $299 for the pill) or compounded semaglutide as cash-pay options.

If you have Medicaid:

1. Check your state's preferred drug list for Wegovy coverage. Most states do not cover.
2. If covered, expect $0 to $10 copays.
3. If not covered, the savings card cannot apply. Novo self-pay is the cleanest cash-pay option at $149 to $349.

If you have no insurance:

1. Apply for Novo Nordisk PAP if household income is at or below 400% FPL.
2. If approved, free drug ships to your provider's office.
3. If not approved, use Novo self-pay ($199 then $349 for the pen, $149 to $299 for the pill) or consider compounded options through a state-licensed compounding pharmacy.

Every Wegovy discount in one dated table (September 2026): price, who qualifies, expiry

This is the table the rest of the article builds toward. Every price was read from the source named on September 4, 2026.

Discount	What you pay	Who qualifies	Expiry or end date	Source
Wegovy Savings Card	As little as $25; Novo pays up to $100 per month, $200 per 2-month fill, $300 per 3-month fill	Commercial insurance that covers Wegovy; not government plans	No end date in the terms; Novo can change them	novocare.com eligibility page
Novo self-pay, pen intro	$199 a month for the first two fills	New self-pay patients (no Wegovy fill in the prior 365 days per GoodRx)	December 31, 2026	NovoCare Price Guide, April 2026; savings-offer page
Novo self-pay, pen ongoing	$349 a month, any dose 0.25 to 2.4 mg	Anyone with a prescription	Open	NovoCare Price Guide
Novo self-pay, Wegovy HD	$399 a month	Anyone with a prescription	Open	wegovy.com
Novo self-pay, Wegovy pill	$149 (1.5 mg), $199 (4 mg), $299 (9 mg and 25 mg)	Anyone with a prescription	The $149 offer on 4 mg ended August 31, 2026	wegovy.com; GoodRx
Medicare GLP-1 Bridge	$50 a month, all pen and pill strengths	Part D beneficiaries meeting CMS BMI criteria; prior authorization	December 31, 2027	CMS; wegovy.com
Patient Assistance Program	$0	Uninsured, at or below 400 percent of the 2026 poverty level ($63,840 for one person); confirm Wegovy is on the list	12-month enrollment	novocare.com PAP page; HHS
GoodRx	Same as Novo self-pay ($149 to $349)	Anyone; it surfaces Novo's offer	Tracks Novo's dates	goodrx.com/wegovy
Retail with no offer	About $1,643 a month	Nobody should	N/A	GoodRx average retail

How long the Wegovy coupon lasts and whether you can use it every month

Two of the most-searched questions about Wegovy coupons are about time, and the current terms answer both.

• Can you use it every month? Yes. The savings card applies to each fill, with the cap set per prescription length: $100 for a 1-month fill, $200 for 2 months, $300 for 3 months. There is no stated limit on the number of fills or months in the terms we read on September 4, 2026.
• How long is it good for? The card carries no expiry date in Novo's current terms, but Novo has changed the terms more than once (a $0 floor and a $225 tier existed in earlier versions), so re-read them at each renewal. The dated items are elsewhere: the $199 pen intro price runs for two fills and through December 31, 2026; the $149 price on the 4 mg pill ended August 31, 2026; the Medicare Bridge runs through December 31, 2027.
• What resets? Nothing in the card resets in January because there is no annual cap; what changes each January is your plan's deductible, and the card does not pay toward that.

Medicare: $50 a month through the GLP-1 Bridge, and the $2,100 Part D cap for everything else

The Medicare section above is right about the card and about the cardiovascular indication, but it predates the Medicare GLP-1 Bridge. From July 1, 2026 through December 31, 2027, eligible Part D beneficiaries (stand-alone Part D or Medicare Advantage with drug coverage) get every strength of the Wegovy pen and pill for $50 a month, with prior authorization through a single central processor. The Part D deductible does not apply and the $50 does not count toward the beneficiary's out-of-pocket total, which for all other covered drugs is capped at $2,100 in 2026 (CMS). CMS criteria: age 18 or older with a BMI of 35 or higher; or a BMI of 30 or higher with heart failure, uncontrolled hypertension despite two antihypertensive medications, or chronic kidney disease stage 3a or above; or a BMI of 27 or higher with pre-diabetes, a previous heart attack, a previous stroke, or symptomatic peripheral artery disease, with BMI judged at the time GLP-1 therapy was started. Beneficiaries who already qualify for Wegovy through Part D, for example under the cardiovascular indication, use that coverage instead, and there the $2,100 cap and the Medicare Prescription Payment Plan apply. Novo's savings-offer page now lists the Bridge price alongside the commercial card.

Coupons that are stale or fake (with the date they stopped being true)

Because coupon pages are copied and rarely updated, these are the figures still circulating in September 2026 that no longer apply.

Claim you will still see	Status	What is true now
"Wegovy for $499 a month through NovoCare"	Superseded; the April 2026 NovoCare Price Guide replaced it	$199 for the first two pen fills, then $349; pill $149 to $299
"Savings card pays up to $225 per fill" or "$0 copay"	Superseded; not in the current terms	$25 floor, $100 monthly cap ($300 per 3-month fill)
"$4,600 annual savings cap"	Not in the current terms	Per-fill caps only
"4 mg pill for $149"	Ended August 31, 2026	$199 for 4 mg; $149 still applies to 1.5 mg
"Medicare never covers Wegovy"	Out of date since July 1, 2026	$50 a month through the GLP-1 Bridge for eligible beneficiaries
"Wegovy coupon code" on a third-party site	There is no code	The savings card and self-pay price come only from Novo; never pay a site for a manufacturer card

A reliable Wegovy discount has three properties: it is published on wegovy.com or novocare.com, it states a dollar cap or price, and it states a date. Anything missing one of the three is worth checking before you plan around it.

January 1, 2027: the $675 list price and what it does to coupon math

Novo Nordisk announced on February 24, 2026 that Wegovy (pen and pill), Ozempic and Rybelsus will carry a $675 monthly U.S. list price from January 1, 2027, down from about $1,350 for Wegovy (CNBC). The coupon terms do not change, but the arithmetic under them does for insured patients: a plan charging 30 percent coinsurance bills $203 instead of $405, and after the card's $100 the patient pays $103 instead of $305. Patients still inside a deductible reach it more slowly, since each fill counts for less. For self-pay patients ($149 to $349) and Medicare Bridge patients ($50) the announcement changes nothing directly. If your plan covers Wegovy with coinsurance, it may be worth waiting until January to start rather than paying a 2026 coinsurance amount in December.

FAQ

Are there real Wegovy coupons in 2026?

Yes. The Novo Nordisk Wegovy savings card is the main coupon. Commercial-insurance patients with covered Wegovy can pay as little as $25 per fill, with Novo covering up to $100 a month. Patients without coverage pay Novo's self-pay price of $149 to $349 depending on product and dose.

Why do so many Wegovy coupon codes online not work?

Most "coupon codes" floating around online refer to the manufacturer savings card, which is free and self-service. Unofficial coupon sites often relist the official program with affiliate links. The official terms only come from Novo Nordisk.

How much is Wegovy at a pharmacy with the savings card?

With commercial insurance covering Wegovy, the card brings a copay of $125 or less down to $25 and cuts higher copays by $100. If your plan does not cover Wegovy, the card does not apply and the self-pay price ($149 to $349) is the fallback. Excludes Medicare, Medicaid, Tricare, VA.

Is WegovyDirect cheaper than the savings card?

Depends on your copay. The card beats self-pay when your copay minus $100 is below $349 for the pen (copays under about $449) or below the pill's $149 to $299. Above that, or with no coverage at all, Novo self-pay is cheaper. Compare both for your situation.

Can Medicare patients get a Wegovy coupon?

The savings card is excluded for Medicare patients, but since July 1, 2026 eligible Part D patients pay $50 a month for any Wegovy pen or pill strength through the Medicare GLP-1 Bridge (through December 31, 2027, prior authorization required). Some Part D plans also cover Wegovy under the cardiovascular indication, where the 2026 out-of-pocket cap of $2,100 applies.

Does GoodRx work for Wegovy?

Only as a window onto Novo's own offer. In September 2026 GoodRx lists Wegovy at as low as $149 against an average retail price of $1,643, and that $149 is Novo's pill price, honored at participating pharmacies. The Novo programs (savings card, self-pay, PAP, Medicare Bridge) are the real discounts.

Can I stack a Wegovy coupon with insurance?

Yes. The savings card stacks with commercial insurance. Insurance pays first, card pays a portion, you pay the remainder, with a floor of $25 and a maximum card contribution of $100 a month. The card cannot stack with Medicare, Medicaid, or Tricare.

Is the Wegovy savings card limited per year?

The current terms (read September 4, 2026) limit savings per fill ($100 per month, $200 per 2-month fill, $300 per 3-month fill) rather than stating an annual dollar cap. Terms can change, so re-read them at each renewal.

How do I sign up for the Wegovy savings card?

Go to the Wegovy website, click savings card, fill out the brief eligibility form, and you'll get a card number, BIN, PCN, and group number. Bring the card to the pharmacy. Activation is free and takes 2 minutes.

Can I use HSA dollars for Wegovy?

Yes. Wegovy is HSA- and FSA-eligible when prescribed for a qualifying medical condition. Paying out of pocket through HSA effectively discounts your Wegovy cost by your federal tax bracket plus any state tax savings.

What if I can't afford Wegovy at any of these prices?

Apply for Novo Nordisk PAP (free if income at or below 400% FPL with no coverage). Consider compounded semaglutide through a state-licensed compounding pharmacy (not FDA-approved, not interchangeable with Wegovy). Talk with your provider about generic liraglutide or other covered alternatives.

Will my employer plan cover Wegovy in 2026?

Coverage rates are growing. In a 2026 survey of 307 employers, 36 percent covered GLP-1s for weight loss and 60 percent for diabetes (healthinsurance.org), and 5 to 10 percent of those covering weight loss plan to drop it in 2027. Check your specific plan's formulary or call HR. Self-funded employer plans set their own rules.

How do I get Wegovy coupons?

There is one real coupon and it is free: enroll for the Wegovy Savings Card on novocare.com, which gives commercially insured patients with coverage a $25 floor and up to $100 a month in savings. Everything else is a price, not a coupon: Novo's self-pay program ($199 then $349 for the pen, $149 to $299 for the pill, September 2026), the $50 Medicare GLP-1 Bridge, and the Patient Assistance Program for low-income uninsured patients.

Which Wegovy discount has the best expiry date?

The Medicare GLP-1 Bridge, which runs through December 31, 2027 at $50 a month for eligible Part D beneficiaries. Next is Novo's $199 pen intro price for new self-pay patients, good for two fills through December 31, 2026. The savings card and the ongoing self-pay prices ($349 pen, $149 to $299 pill) carry no stated end date, which means Novo can change them at any time, as it did in April 2026.

Can I use the Wegovy coupon every month?

Yes. The savings card applies to every fill for as long as you have commercial insurance that covers Wegovy, with the savings capped at $100 per 1-month prescription, $200 per 2-month and $300 per 3-month (terms read September 4, 2026). There is no fill count or annual dollar cap in the current terms. If your copay is above $125 you will pay the excess each month, so compare with Novo's self-pay price.

Related guides

• Where Can I Get Zepbound Cheap in 2026: Every Real Option, Ranked by Total Cost
• Where to Get Tirzepatide Cheap in 2026: Every Real Option Ranked by Cost
• Wegovy Coupons in 2026: Which Savings Programs Actually Reduce Your Cost (And Which Don't)
• Novo Nordisk Wegovy Coupon in 2026: Who Qualifies, How Much You'll Actually Save, and What to Do When Denied
• What Is the Least Expensive Semaglutide Option in 2026? Every Route Compared
• Does GoodRx Cover Wegovy? Why This Question Reveals a Dangerous Misunderstanding About Discount Cards

Sources

1. Novo Nordisk. Wegovy prescribing information, revised 2024.
2. Novo Nordisk. Wegovy savings card terms and conditions, April 2026.
3. Novo Nordisk. WegovyDirect program details, April 2026.
4. Novo Nordisk Patient Assistance Program eligibility, April 2026.
5. Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389:2221-2232.
6. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
7. Centers for Medicare & Medicaid Services. Memo on Wegovy coverage under Medicare Part D for cardiovascular indication, March 2024.
8. Centers for Medicare & Medicaid Services. Inflation Reduction Act drug pricing provisions, 2025 implementation.
9. Office of Inspector General, HHS. Special advisory bulletin on offering gifts to Medicare and Medicaid beneficiaries.
10. Internal Revenue Service. Publication 502, medical and dental expenses, 2025.
11. Kaiser Family Foundation. Coverage of GLP-1s for obesity in commercial plans, 2025 analysis.
12. Novo Nordisk (NovoCare). Wegovy Savings Card eligibility and terms, read September 4, 2026. https://www.novocare.com/eligibility/wegovy-savings-card.html
13. Novo Nordisk (NovoCare). Wegovy savings offer page, read September 4, 2026. https://www.novocare.com/patient/medicines/wegovy/savings-offer.html
14. Novo Nordisk (NovoCare). Wegovy Price Guide, US26NC00049, April 2026. https://www.novocare.com/content/dam/novonordisk/novocare/redesign/pdf/Wegovy_Price_Guide.pdf
15. Novo Nordisk. What to pay for Wegovy, self-pay and savings offer pricing, read September 4, 2026. https://www.wegovy.com/obesity/what-to-pay-for-wegovy.html
16. GoodRx. Wegovy prices and self-pay offer, read September 4, 2026. https://www.goodrx.com/wegovy
17. Centers for Medicare and Medicaid Services. Medicare GLP-1 Bridge model overview, read September 4, 2026. https://www.cms.gov/priorities/innovation/innovation-models/medicare-glp-1-bridge
18. Centers for Medicare and Medicaid Services. Medicare GLP-1 Bridge: information for providers, page last modified August 6, 2026. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-providers
19. Centers for Medicare and Medicaid Services. Final CY 2026 Part D redesign program instructions fact sheet, March 2026. https://www.cms.gov/newsroom/fact-sheets/final-cy-2026-part-d-redesign-program-instructions
20. Novo Nordisk (NovoCare). Patient Assistance Program eligibility for 2026, read September 4, 2026. https://www.novocare.com/diabetes/help-with-costs/pap.html
21. U.S. Department of Health and Human Services, ASPE. 2026 poverty guidelines. https://aspe.hhs.gov/poverty-guidelines
22. CNBC. Novo Nordisk to slash Wegovy, Ozempic U.S. list prices by up to 50 percent, February 24, 2026. https://www.cnbc.com/2026/02/24/novo-nordisk-to-slash-wegovy-ozempic-us-list-prices-by-up-to-50percent.html
23. healthinsurance.org (Louise Norris). Does health insurance cover GLP-1 medications for weight loss?, updated August 20, 2026. https://www.healthinsurance.org/faqs/does-health-insurance-cover-drugs-used-for-weight-loss-such-as-ozempic-wegovy-mounjaro-and-zepbound/
24. FormBlends Research. Compounded GLP-1 Price Index, as of September 3, 2026. https://formblends.com/feeds/glp1-prices.json

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy and Ozempic are registered trademarks of Novo Nordisk A/S. GoodRx is a registered trademark of GoodRx Holdings, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.